Young AH

Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE5 8AB, United Kingdom; Division of Psychiatry, Department of Brain Sciences, Imperial College London, United Kingdom.

48 papers · 3 preprints · ORCID

ArticlePsychedelics

The effect of psychedelics on associative learning: A systematic review.

Caulfield A, Li L, Belessiotis-Richards C +5

Young AH

The effect of psychedelics on associative learning: A systematic review.

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.

Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.

Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.

Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.

Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study.

Regional Blood Flow Signatures of Opioidergic Modulation of Ketamine in Major Depressive Disorder: A Randomized Crossover Study.

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience.

Learning as the unifying mechanism of psychedelic action.

A long, strange trip: Ketamine treatment in psychiatry.

(Es)ketamine as a treatment for depressive episodes with psychotic features: systematic review.

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Regional blood flow signatures of opioidergic modulation of ketamine in major depressive disorder: a randomised crossover study

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

The effect of psychedelics on associative learning: a systematic review

Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review.

A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy volunteers.

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial - ERRATUM.

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.

Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.

Is it now time to prepare psychiatry for a psychedelic future?

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.

Guidelines for ketamine use in clinical psychiatry practice.

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-&lt;i&gt;N,N&lt;/i&gt;-dimethyltryptamine benzoate) in healthy participants.

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.

Ketamine cystitis following ketamine therapy for treatment-resistant depression - case report.

Corrigendum: Ceremonial ayahuasca in amazonian retreats-mental health and epigenetic outcomes from a six-month naturalistic study.

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.

Psychedelics for treatment resistant depression: are they game changers?

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.

Science, safety and education: Informing the psychedelic treatment of psychiatric disorders.

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations.

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD).

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.

Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.

Ceremonial Ayahuasca in Amazonian Retreats-Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study.

Psilocybin: From Serendipity to Credibility?

The pharmacological interaction of compounds in ayahuasca: a systematic review.

Psychedelic treatment of functional neurological disorder: a systematic review.

Psychedelics in the treatment of unipolar mood disorders: a systematic review.

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participants.